

Abstract



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(21) International Patent Classification ⁷ : G01N 33/52, 33/68		A1	(11) International Publication Number: WO 00/45168
			(43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/EP00/00689 (22) International Filing Date: 27 January 2000 (27.01.00) (30) Priority Data: 9901775.8 28 January 1999 (28.01.99) GB 9907790.1 7 April 1999 (07.04.99) GB (71) Applicant (for all designated States except US): UNIVERSITE DE GENEVE [CH/CH]; Rue General-Dufour 24, Case Postale, CH-1211 Geneva (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): BIENVENUT, Willy, Vincent [FR/FR]; 4 Route Des Mauds, F-17460 Thénac (FR). HOCHSTRASSER, Denis, Francois [CH/CH]; Chemin de la Savonnière, Collonge-Bellerive, CH-1245 Geneva (CH). SANCHEZ, Jean-Charles [CH/CH]; Chemin Frank-Thomas 42, CH-1208 Geneva (CH). (74) Agent: LUCAS, Brian, Ronald; Lucas & Co., 135 Westhall Road, Warlingham, Surrey CR6 9HJ (GB).		(81) Designated States: AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND KIT FOR IDENTIFYING OR CHARACTERISING POLYPEPTIDES			
(57) Abstract <p>Polypeptides which have been separated by gel electrophoresis can be identified or characterised by a procedure which has two main stages. In the first stage the gel is digested with a polypeptide-cleaving agent such as an enzyme. This produces mainly large fragments which, in the second stage are electroblotted through a hydrophilic membrane on which is immobilised another polypeptide-cleaving reagent such as an enzyme onto a hydrophobic member, typically a membrane, e.g. of PVDF. The resulting fragments, usually peptides, are identified, preferably by MALDI-TOF MS, or a property may be determined, e.g. by interaction with an antibody.</p>			